Literature DB >> 11021998

Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.

K A Bernard1, W B Klimstra, R E Johnston.   

Abstract

The arbovirus, Venezuelan equine encephalitis virus (VEE), causes disease in humans and equines during periodic outbreaks. A murine model, which closely mimics the encephalitic form of the disease, was used to study mechanisms of attenuation. Molecularly cloned VEE viruses were used: a virulent, epizootic, parental virus and eight site-specific glycoprotein mutants derived from the parental virus. Four of these mutants were selected in vitro for rapid binding and penetration, resulting in positive charge changes in the E2 glycoprotein from glutamic acid or threonine to lysine (N. L. Davis, N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith, and R. E. Johnston, Virology 183, 20-31, 1991). Tissue culture adaptation also selected for the ability to bind heparan sulfate as evidenced by inhibition of plaque formation by heparin, decreased infectivity for CHO cells deficient for heparan sulfate, and tight binding to heparin-agarose beads. In contrast, the parental virus and three other mutants did not use heparan sulfate as a receptor. All eight mutants were partially or completely attenuated with respect to mortality in adult mice after a subcutaneous inoculation, and the five mutants that interacted with heparan sulfate in vitro had low morbidity (0-50%). These same five mutants were cleared rapidly from the blood after an intravenous inoculation. In contrast, the parental virus and the other three mutants were cleared very slowly. In summary, the five VEE viruses that contain tissue-culture-selected mutations interacted with cell surface heparan sulfate, and this interaction correlated with low morbidity and rapid clearance from the blood. We propose that one mechanism of attenuation is rapid viral clearance in vivo due to binding of the virus to ubiquitous heparan sulfate. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021998     DOI: 10.1006/viro.2000.0546

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  126 in total

1.  An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety.

Authors:  M L Heil; A Albee; J H Strauss; R J Kuhn
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Heparan sulfate-independent infection attenuates high-neurovirulence GDVII virus-induced encephalitis.

Authors:  Honey V Reddi; A S Manoj Kumar; Aisha Y Kung; Patricia D Kallio; Brian P Schlitt; Howard L Lipton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

4.  Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection.

Authors:  Atsushi Tanaka; Uranan Tumkosit; Shota Nakamura; Daisuke Motooka; Natsuko Kishishita; Thongkoon Priengprom; Areerat Sa-Ngasang; Taroh Kinoshita; Naokazu Takeda; Yusuke Maeda
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

5.  Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

Authors:  M E Fluet; A C Whitmore; D A Moshkoff; K Fu; Y Tang; M L Collier; A West; D T Moore; R Swanstrom; R E Johnston; N L Davis
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

6.  Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipid-conjugated heparin.

Authors:  Jolanda M Smit; Barry-Lee Waarts; Koji Kimata; William B Klimstra; Robert Bittman; Jan Wilschut
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein.

Authors:  Yuanming Zhang; John C Rassa; Maria Elena deObaldia; Lorraine M Albritton; Susan R Ross
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.

Authors:  Patricia V Aguilar; Slobodan Paessler; Anne-Sophie Carrara; Samuel Baron; Joyce Poast; Eryu Wang; Abelardo C Moncayo; Michael Anishchenko; Douglas Watts; Robert B Tesh; Scott C Weaver
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues.

Authors:  Chun-Liang Chen; S Saif Hasan; Thomas Klose; Yingyuan Sun; Geeta Buda; Chengqun Sun; William B Klimstra; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-03       Impact factor: 11.205

10.  A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads.

Authors:  Tyler R Prestwood; Daniil M Prigozhin; Kristin L Sharar; Raphaël M Zellweger; Sujan Shresta
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.